Related Experiment Videos
[Fetal and neonatal immune thrombocytopenias. Study group "Mother-child immune thrombopenias"]
C Kaplan1, M C Morel-Kopp, E Verdy
1Service d'Immunologie leuco-plaquettaire, Institut National de Transfusion Sanguine, Paris.
Insights
Advances in platelet immunology and fetal therapy have improved neonatal thrombocytopenia outcomes. While in-utero treatments manage alloimmunization, prenatal options for maternal autoimmune thrombocytopenia remain ineffective.
Area of Science:
- Neonatal immunology
- Fetal therapy
- Platelet disorders
Context:
- Neonatal thrombocytopenia poses significant risks, including cerebral hemorrhage, death, and neurological sequelae.
- Recent advancements in platelet immunology and fetal therapy have enhanced management strategies.
- Accurate etiological diagnosis is crucial for effective treatment and future pregnancy management.
Purpose:
- To review the impact of recent advances on neonatal thrombocytopenia management.
- To highlight the efficacy of in-utero treatments for specific causes of fetal thrombocytopenia.
- To identify current limitations in prenatal treatment for autoimmune-related thrombocytopenia.
Summary:
- Fetal therapy, particularly in-utero treatments for fetomaternal alloimmunization, has significantly improved outcomes for affected pregnancies.
- Establishing the cause of immune thrombocytopenia allows for targeted treatment and improved management of subsequent pregnancies.
- Currently, no prenatal treatments are effective for thrombocytopenia arising from maternal autoimmunity.
Impact:
- Improved management of pregnancies at risk for fetal thrombocytopenia.
- Enhanced understanding of platelet immunology in neonatal settings.
- Identifies a critical unmet need for prenatal therapies for autoimmune-induced neonatal thrombocytopenia.
Abstract:
Neonatal thrombocytopenia has benefited from the advances achieved during the last few years in platelet immunology and foetal therapy. The major risk of the disease is cerebral haemorrhage resulting in death or neurological sequelae. Establishing the aetiological diagnosis of immune thrombocytopenia makes it possible nowadays to apply the appropriate treatment and eventually to take care of future pregnancies. Treatments in utero of foeto-maternal alloimmunization have radically altered the natural course of foetal thrombocytopenia, thereby permitting the management of pregnancies at risk. On the other hand, so far no prenatal treatment has proved to be effective against thrombocytopenia due to maternal autoimmunity.